Label: information for the user
Enbrel 10 mg powder and solvent for injectable solution for pediatric use
etanercept
Read this label carefully before starting to use this medicine, because it contains important information for you.
|
The information inthislabel is organizedinthe following 7 sections:
1.What Enbrel is and what it is used for
2.What you need to know before starting to use Enbrel
3.How to use Enbrel
Enbrel is a medication made from two human proteins. It blocks the activity of another protein found in the body that produces inflammation. Enbrel acts by reducing the inflammation associated with certain diseases.
Enbrel is indicated for the treatment of the following diseases in children and adolescents:
No use Enbrel
Warnings and Precautions
Consult your doctor before starting to use Enbrel.
Patients with severe rheumatoid arthritis, who have had the disease for a long time, may be at higher risk of developing lymphoma.
Children and adults taking Enbrel may be at increased risk of developing lymphoma or other cancers.
Some adolescent and child patients who have received Enbrel or other medications that work in the same way as Enbrel have developed cancers, including rare types, which sometimes resulted in death.
Some patients taking Enbrel have developed skin cancers. Inform your doctor if the child develops any changes in skin appearance or growths on the skin.
Children and Adolescents
Vaccinations:If possible, children should have all vaccinations updated before using Enbrel. Some vaccines, such as the oral polio vaccine, should not be administered while using Enbrel. Consult the child's doctor before administering any vaccine.
Enbrel should not normally be used in children under 2 years with polyarthritis or oligoarthritis, in children under 12 years with arthritis related to enthesitis or psoriatic arthritis, or in children under 6 years with psoriasis.
Other Medications and Enbrel
Inform your doctor or pharmacist if the child is using, has used recently, or may need to use any other medication (including anakinra, abatacept, or sulfasalazine), even those not prescribed by the child's doctor. The child should not use Enbrel with medications containing anakinra or abatacept.
Pregnancy and Breastfeeding
Enbrel should only be used during pregnancy if clearly necessary. Consult your doctor if you are pregnant, think you may be pregnant, or plan to become pregnant.
If you have received Enbrel during pregnancy, your baby may be at increased risk of infection. Additionally, in one study, more birth defects were observed when the mother had received Enbrel during pregnancy, compared to mothers who had not received Enbrel or similar medications (TNF antagonists), but no pattern was observed in the types of birth defects reported. Another study found no increased risk of congenital defects when the mother had received Enbrel during pregnancy. Your doctor will help you decide if the benefits of treatment outweigh the potential risk to your baby.
Consult your doctor if you wish to breastfeed while on Enbrel treatment. It is essential to inform the pediatrician and other healthcare professionals about Enbrel use during pregnancy and breastfeeding before your baby receives any vaccine.
Driving and Operating Machinery
It is not expected that Enbrel use will affect your ability to drive and operate machinery.
Use in Children and Adolescents
Follow exactly the administration instructions for this medication as indicated by your doctor. If in doubt, consult your doctor or pharmacist again.
If you estimate that the action of Enbrel is too strong or too weak, inform your doctor or pharmacist.
The appropriate dose and dosing frequency will depend on the child's or adolescent's body weight and disease. Your doctor will instruct you on how to prepare and measure the appropriate dose.
The 10 mg vial is for children who have been prescribed a dose equal to or less than 10 mg. Each vial is for single use and for a single patient, and any remaining solution in the vial should be discarded.
For extended polyarthritis or oligoarthritis in patients aged 2 years or older, or psoriatic arthritis related to enthesitis or psoriatic arthritis in patients aged 12 years or older, the usual dose is 0.4 mg of Enbrel per kg of body weight (up to a maximum of 25 mg) twice a week, or 0.8 mg of Enbrel per kg of body weight (up to a maximum of 50 mg) once a week.
For psoriasis in patients aged 6 years or older, the usual dose is 0.8 mg of Enbrel per kg of body weight (up to a maximum of 50 mg) once a week. If Enbrel has no effect on the child's disease after 12 weeks, your doctor may instruct you to stop using this medication.
Form and Route of Administration
Enbrel is administered by subcutaneous injection under the skin.
Enbrel can be administered with or without food or beverages.
The powder must be dissolved before use.In Section 7, “Instructions for Use”, detailed instructions for preparing and injecting Enbrel are included.Enbrel solution should not be mixed with any other medication.
It may be helpful to note in a diary what days of the week you should use Enbrel.
If You Use More Enbrel Than You Should
If you use more Enbrel than you should (either by injecting a large amount at one time or by using it too frequently), you should speak with a doctor or pharmacist immediately. Always carry the medication packaging with you, even if it is empty.
If You Forget to Inject Enbrel
If you forget a dose, you should inject it as soon as you remember, unless the next dose is due the following day, in which case you should omit the missed dose. Then, continue injecting the medication on the usual days. If you do not remember until the day you are due to administer the next dose, do not administer a double dose (2 doses on the same day) to compensate for the missed dose.
If You Interrupt Treatment with Enbrel
Your symptoms may return after treatment is interrupted.
If you have any other questions about using this medication, ask your doctor or pharmacist.
Allergic reactions
If you notice any of the following reactions in the child, do not administer Enbrel to the child again. Inform your doctor immediately or take the child to the nearest hospital emergency department.
Severe allergic reactions are rare. If the child presents any of the above symptoms, it may be due to an allergic reaction to Enbrel, so you must seek urgent medical attention immediately.
Severe side effects
If you notice any of the following side effects, the child may need emergency medical attention.
These side effects are rare or uncommon, but are serious conditions (some of which may be fatal in rare cases). If these signs occur, inform your doctor immediately or go to the nearest hospital emergency department.
The following are known side effects of Enbrel, grouped by decreasing frequency:
Infections (including colds, sinusitis, bronchitis, urinary tract infections, and skin infections); reactions at the injection site (including bleeding, bruising, redness, itching, pain, and swelling) (do not occur as frequently after the first month of treatment; some patients have developed a reaction at the injection site that they had recently used); and headache.
Allergic reactions; fever; rash; itching; and autoantibodies directed against normal tissues (formation of autoantibodies).
Severe infections (including pneumonia, non-superficial skin infections, joint infections, blood infections, and generalized infections); worsening of congestive heart failure; low red blood cell count, low white blood cell count, low neutrophil count (a type of white blood cell); low platelet count; skin cancer (excluding melanoma); localized skin swelling (angioedema); urticaria (prominent skin rashes, red or pale, often accompanied by itching); eye inflammation, psoriasis (new or worsening); inflammation of blood vessels affecting multiple organs; increased liver enzymes in blood tests (in patients also receiving methotrexate, the increase in liver enzymes is common); abdominal cramps and pain, diarrhea, weight loss, or blood in the stool (signs of intestinal problems).
Severe allergic reactions (including localized severe skin swelling and labored breathing); lymphoma (a type of blood cancer); leukemia (cancer affecting the blood and bone marrow); melanoma (a type of skin cancer); combined low red blood cell, white blood cell, and platelet count; nervous system disorders (with severe muscle weakness and symptoms and signs similar to multiple sclerosis or inflammation of the optic nerves or spinal cord); tuberculosis; congestive heart failure of new onset; seizures; lupus or lupus-like syndrome (symptoms may include persistent rash, fever, joint or muscle pain, or fatigue); skin eruption, which may lead to severe blistering and peeling of the skin; lymphoid reactions (skin eruption, pruritic, red-brown, and/or white-gray lines on mucous membranes); autoimmune hepatitis caused by the immune system (in patients also receiving methotrexate, the frequency is uncommon); immunological disorder that may affect the lungs, skin, and lymph nodes (sarcoidosis); inflammation or scarring of the lungs (in patients also receiving methotrexate, the frequency of inflammation or scarring of the lungs is uncommon); damage to the small filters within the kidneys, leading to impaired kidney function (glomerulonephritis).
Failure of the bone marrow to produce critical blood cells.
Merkel cell carcinoma (a type of skin cancer); Kaposi's sarcoma, a rare cancer related to human herpes virus 8 infection. Kaposi's sarcoma usually manifests as purple skin lesions;excessive activation of white blood cells associated with inflammation (macrophage activation syndrome); reactivation of hepatitis B (a liver infection);worsening of a disease called dermatomyositis (inflammation and weakness of the muscles accompanied by skin rash).
Other side effects in children and adolescents
The side effects observed in children and adolescents, as well as their frequencies, are similar to those previously described.
Reporting side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this prospectus. You can also report them directly through the Spanish System for the Vigilance of Medicinal Products for Human Use:www.notificaRAM.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging after “EXP”. The expiration date is the last day of the month indicated.
Store in the refrigerator (2 °C – 8 °C). Do not freeze.
Before preparing the Enbrel solution, it can be stored at room temperature up to a maximum of 25 °C, and for a single period of up to 4 weeks; after which, the medication cannot be refrigerated again. Enbrel must be discarded if not used within 4 weeks following its removal from the refrigerator. It is recommended to note the date when Enbrel was removed from the refrigerator and the date from which Enbrel must be discarded (not exceeding 4 weeks from the removal of the packaging from the refrigerator). This new date must not exceed the expiration date that appears on the packaging.
After preparing the Enbrel solution, immediate use is recommended. However, the solution can be used within 6 hours if stored at a maximum temperature of 25 °C.
Do not use this medication if you observe that the solution is not transparent or contains particles. The solution must be transparent, colorless to pale yellow or pale brown, without lumps, scales, or particles.
Medications must not be thrown down the drain or in the trash. Ask your pharmacist how to dispose of the packaging and medications that you no longer need. In this way, you will help protect the environment.
Enbrel Composition
The active ingredient of Enbrel is etanercept. Each vial of Enbrel 10 mg powder and diluent for injectable solution for pediatric use contains 10 mg of etanercept. Once reconstituted, the solution contains 10 mg/ml of etanercept.
The other components are:
Powder: Mannitol (E421), sucrose, and tromethamine.
Diluent: Water for injection.
Appearance of the product and content of the container
Enbrel 10 mg powder and diluent for injectable solution for pediatric use is presented as a white powder with a diluent for injectable solution (powder for injection). Each container contains 4 vials, 4 preloaded syringes of water for injection, 4 needles, 4 vial adapters, and 8 alcohol wipes.
Marketing Authorization Holder: Pfizer Europe MA EEIG Boulevard de la Plaine 17 1050 Bruxelles Belgium | |
Manufacturer: Pfizer Manufacturing Belgium NV Rijksweg 12, 2870 Puurs-Sint-Amands Belgium |
For more information about this medicine, please contact the local representative of the marketing authorization holder:
Spain
Pfizer, S.L.
Tel: +34 91 490 99 00
Last review date of this leaflet:
The detailed information about this medicine is available on the website of the European Medicines Agency:http://www.ema.europa.eu.
7.Instructions for use
This section is divided into the following subsections:
a.Introduction
b.Preparing for the injection
c.Preparing the Enbrel dose for injection
d.Adding the diluent
e.Extracting the Enbrel solution from the vial
f.Placing the needle in the syringe
g.Choosing an injection site
h.Preparing the injection site and injecting the Enbrel solution
i.Disposal of materials
a.Introduction
The following instructions explain how to prepare and inject Enbrel. Read these instructions carefully and follow them step by step. The child's doctor or nurse will teach you the proper technique for administering an injection and the amount to administer to the child. Do not attempt to administer an injection to the child until you are sure you understand how to prepare and administer the injection.
This injection should not be mixed in the same syringe or vial with any other medicine. See section 5 for instructions on how to store Enbrel.
b.Preparing for the injection
1 Enbrel vial
1 Preloaded syringe containing a transparent and colorless diluent (water for injection)
1 Needle
1 Vial adapter
2 Alcohol wipes
c.Preparing the Enbrel dose for injection
Figure 1
Figure 2 | Figure 3 | Figure 4 |
CORRECT | INCORRECT |
Figure 5
Figure 6
Figure 7
d.Adding the diluent
Figure 8
Figure 9
e.Extracting the Enbrel solution from the vial
Figure 10
Figure 11
Figure 12
f.Placing the needle in the syringe
Figure 13
Figure 14
Figure 15
Figure 16
g.Choosing an injection site
Figure 17
h..Preparing the injection site and injecting the Enbrel solution
Figure 18
Figure 19
i.Disposal of materials
If you have any questions, consult a doctor, nurse, or pharmacist who is familiar with the use of Enbrel.
Tem perguntas sobre este medicamento ou sintomas? Obtenha orientação de um médico qualificado, de forma prática e segura.